$CROX

Crocs Soars After Raising Its Outlook. Here’s Which ETFs Own the Stock

Crocs (CROX) shares rose 26.06% after reporting Q3 adjusted EPS of $3.69, beating estimates, and raising full-year 2026 guidance. Revenue grew to $1.04B, exceeding expectations. CEO Andrew Rees attributed growth to disciplined brand strategies. The stock is held in small/mid-cap and consumer discretionary ETFs, but its impact on fund returns is limited due to its small weight.

Original reporting
Published Oct 29, 2026, 4:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 4:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Crocs Soars After Raising Its Outlook. Here’s Which ETFs Own the Stock — source image
Decision brief

The 30-second read

$CROXBullishHigh
01

Why it matters

The earnings beat and guidance raise are likely to attract buying pressure, especially in small‑cap focused funds.

02

Market read

Fresh earnings data with a sizable price move makes this a high‑impact news item for traders.

03

What to watch

Potential inventory buildup and debt servicing could temper upside.

Relevance 8/10Novelty 8/10Timing: intraday today

Background

Crocs, a consumer‑cyclical footwear company, posted Q3 results that beat expectations and lifted its full‑year EPS outlook.

Company-level read

Ticker impact

$CROXBullishHigh confidence
Context

Crocs reported Q3 earnings beat and raised full-year 2026 EPS guidance, driving a 26% intraday rally.

Expected impact

likely upward pressure as investors price in higher earnings expectations

Evidence & confidence

The earnings beat and higher guidance are fresh, material information for a mid‑cap stock, prompting immediate buying interest.

Market effects

Boosts consumer discretionary and footwear subsector sentiment.

U.S. small‑cap indices may see modest lift from the rally.

Limited to U.S. markets; no broader macro effect.

Counterpoint

The rally may be overblown if guidance growth slows in Q4.

Key entities

  • Crocs, Inc.

    Footwear manufacturer reporting earnings.

Related articles

$CROXMed

UBS raises Crocs stock price target to $145 on strong results

UBS raised its price target on Crocs (CROX) to $145 from $120, citing strong Q3 results and raised guidance. The stock has surged 26% in a week. UBS noted macro uncertainty but sees balanced risk. Crocs reported adjusted earnings of $3.69 per share and revenue of $1.04B, exceeding expectations. Goldman Sachs also raised its target to $128 but maintained a Sell rating.

$CROXMed

Goldman Sachs raises Crocs stock price target on growth outlook

Goldman Sachs raised its price target on Crocs (CROX) to $128 from $95, citing stronger growth, improved profitability, and a positive outlook. The stock has surged 75.7% year-to-date. Crocs reported stronger-than-expected Q3 results, with adjusted earnings of $3.69 per share and revenue of $1.04 billion, raising its full-year outlook. The HEYDUDE brand showed positive performance after two years of negative results.

$CROXHighAI 9/10

"I thought ugly shoes were a thing of the past"... Crocs shares stage stunning turnaround after plunging 30%

Crocs shares surged 25.54% to $150.26 after strong Q3 results and an upgraded full-year outlook. Adjusted EPS of $3.69 beat estimates, and revenue reached $1.04 billion. HEYDUDE, a subsidiary, saw a 6.1% revenue increase. CEO Andrew Rees cited growth across brands and regions. Last year, shares plunged 30% due to weak guidance and market trends.